Company

Dyve Biosciences created a breakthrough platform technology that broadly enables transdermal drug delivery. Dyve has advanced clinical programs in gout and melasma that demonstrate the power and potential of the technology.

Dyve’s platform technology is a simple drug development model.  Dyve uses existing drugs with proven safety and efficacy to enable an efficient use of resources and fast development timelines while mitigating drug development and investor risk.

  • Safe, existing molecules
  • Delivery challenge
  • Novel or generic
  • Existing or new indications
  • Penetration of molecules with delivery challenges
  • Strong safety history
  • Rapid prototyping
  • Scalable manufacturing
  • Enhanced efficacy
  • Higher compliance
  • Better pharmacokinetics
  • Lower adverse events